Ambiguous TP53 Variant in a Familial Cancer Workup
A 41-year-old woman with early-onset breast cancer (age 38) and a mother who had ovarian cancer at 52 undergoes germline panel testing. The laboratory reports a TP53 variant, c.733G>A, classified as a variant of uncertain significance (VUS). The variant lies in the DNA-binding domain and is predicted damaging by three in silico tools, but population databases list it at a frequency of 0.0004 in one subpopulation. Tumor testing from the patient shows loss of heterozygosity at the TP53 locus with the variant allele retained. The oncologist asks whether to offer risk-reducing surgery and cascade testing to relatives, given the VUS.
1. Assess whether the evidence supports reclassifying this variant, citing the specific criteria that apply.
Read the worked answer
Several ACMG/AMP criteria can be evaluated. The variant is rare but present at 0.0004 in one subpopulation, which is above the threshold typically used for PM2 (absent or extremely rare), so PM2 should not be applied. In silico predictions (multiple tools agreeing) support PP3 but are weak evidence alone. The key finding is tumor LOH with retention of the variant allele, which is consistent with loss of the wild-type allele and supports a functional impact; however, LOH alone is not a formal criterion and must be interpreted cautiously because LOH occurs in many tumors. To reclassify toward likely pathogenic, the lab would need functional assays (e.g., transactivation or yeast growth assays) or segregation data. On current evidence the variant remains a VUS; the in silico and LOH findings are suggestive but insufficient.
2. What is the appropriate clinical management and family counseling while the variant remains a VUS?
Read the worked answer
Management should be based on the patient's personal and family history rather than the VUS itself. Because she has early-onset breast cancer and a first-degree relative with ovarian cancer, she already meets criteria for hereditary cancer evaluation independent of the VUS, and risk-reducing salpingo-oophorectomy and enhanced breast surveillance can be discussed on that basis. Cascade testing of relatives for the VUS should not be used to make irreversible decisions; relatives should be offered testing only in a research or reclassification context, and counseling must explain that a VUS result does not confirm or exclude hereditary risk. The family should be advised to recontact the genetics service periodically in case the variant is reclassified.
3. The laboratory later performs a functional transactivation assay showing the variant abolishes p53 transcriptional activity. How does this change the classification and the plan?
Read the worked answer
A validated functional assay demonstrating loss of transactivation provides strong functional evidence (PS3) when the assay is well established and controls behave correctly. Combined with the rare frequency and in silico support, PS3 plus PP3 and the clinical context can move the variant from VUS to likely pathogenic. That reclassification changes counseling: cascade testing becomes actionable, and relatives who carry the variant can be offered enhanced surveillance and risk-reducing options. The patient's own management is reinforced, and the family should be re-contacted. The laboratory should document the assay, its validation, and the evidence codes so the reclassification is transparent and reproducible.